Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Emergent Biosolutions (EBS) is now available.
Emergent BioSolutions Inc. has successfully completed the sale of its Baltimore-Camden drug product facility to a subsidiary of Bora Pharmaceuticals, securing roughly $30 million at the deal’s closing. This strategic move, subject to standard post-closing adjustments, marks a significant financial event for the company, capturing the interest of stock market enthusiasts.
See more data about EBS stock on TipRanks’ Stock Analysis page.